Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis

BACKGROUND: Little is known about the prognostic difference of anti-EGFR therapy, cetuximab (CTX) or nimotuzumab (NTZ), concurrently with induction chemotherapy (IC, investigational arm) or RT (control arm) for patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We conducted thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Hao, Tang, Ling-Long, Liu, Xu, Chen, Lei, Li, Wen-Fei, Mao, Yan-Ping, Zhang, Yuan, Liu, Li-Zhi, Tian, Li, Guo, Ying, Sun, Ying, Ma, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870169/
https://www.ncbi.nlm.nih.gov/pubmed/29580204
http://dx.doi.org/10.1186/s12885-018-4268-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870169/
https://www.ncbi.nlm.nih.gov/pubmed/29580204
http://dx.doi.org/10.1186/s12885-018-4268-y

Ejemplares similares